Image Source: UnsplashAn IntroductionThe 10 clinical-stage AI-focused (designated with *) and psychedelic compound-based (designated with **) drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD in July after having gone DOWN 13.2%, on average, in June and are now UP 13.8%, on average, YTD.
The munKNEE Clinical-Stage BioTech Drug Stocks Portfolio
Below are the stock performances of the 10 constituents in the Portfolio last week, MTD and YTD, a description of their areas of focus, current market capitalizations and the latest news, analyses and commentary where pertinent:
- Area of Focus: specializes in developing an artificial intelligence-driven allosteric drug-discovery platform intended to detect and characterize interactions that occur on a protein of interest and combines computational methods with experimental approaches across the fields of structural biology, biophysics, and chemistry. Its initial focus on precision oncology and genetic diseases.
- Market Capitalization: $1090M
- Latest News, Analyses and Commentary: None
- Area of Focus: focuses on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
- Market Capitalization: $456M
- Latest News, Analyses and Commentary: None
- Area of Focus: focuses on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Market Capitalization: $258M
- Latest News, Analyses and Commentary:
- atai Exploring Psychedelic Frontiers
- Area of Focus: develops antibody therapeutics and then outsources their initial findings to their partners for further drug discovery.
- Market Capitalization: $917M
- Latest News, Analyses and Commentary:
- AbCellera Biologics Upgraded to Buy: Here’s What You Should Know
- Area of Focus: has one of the world’s most extensive biological and chemical datasets and has several compounds in phase 1 and 2 studies, including a small molecule therapeutic for cavernous cerebral malformation and another for neurofibromatosis type 2.
- Market Capitalization: $2,240M
- Latest News, Analyses and Commentary:
- Is Recursion Pharmaceuticals Stock a Buy?
- Area of Focus: focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Market Capitalization: $477M
- Latest News, Analyses and Commentary:
- atai
- Area of Focus: specializes in offering solutions for both small molecule discovery and biologics discovery focusing on structure prediction and protein engineering, including antibody modeling.
- Market Capitalization: $1,630M
- Latest News, Analyses and Commentary:
- Gene Editing Stock Schrödinger Actually Making Money
- Area of Focus: focuses on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- Market Capitalization: $536M
- Latest News, Analyses and Commentary:
- MindMed to be Included in Russell 2000® and Russell 3000® Indexes
- Area of Focus: focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
- Market Capitalization: $624M
- Latest News, Analyses and Commentary:
- 3 Psychedelic Stocks to Ride to the Moon and Beyond
- Area of Focus: reported the first AI-designed drug candidate to enter clinical trials and is collaborating with Bristol-Myers Squibb on a handful of drug candidates and has partnered with Sanofi, GSK and PathAI on drug discovery projects.
- Market Capitalization: $639M
- Latest News, Analyses and Commentary:
- Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
SummaryOn average,
More By This Author:Canadian Cannabis LPs Doubled Performance Of American MSOs This Week
All But 1 Of 6 Semiconductor Segments Outperformed The Nasdaq This Week
A Comparative Analysis Of The 12 Largest Cannabis Companies Puts Green Thumb #1
